Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEWARK, Calif.: NEWARK, Calif., June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,503,311 shares of its common stock, including 456,953 shares sold pursuant to the underwriters' exercise in full of their "green...

Click to view original post